|
作者 |
Berardi, Francesco;Abate, Carmen;Ferorelli, Savina;de Robertis, Anna F.;Leopoldo, Marcello;Colabufo, Nicola A.;Niso, Mauro;Perrone, Roberto; |
|
|
[摘要]:arylpiperazines previously studied and structurally related to some s receptors ligands were preliminarily screened. Consequently, a novel series of 2- or 2,6-disubstituted (CH3, CH3O, Cl, F) cis- and trans-4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines was developed. Radioreceptor binding assays evidenced cis-19, cis-30 and cis-33 as new ligands with nanomolar affinity toward EBP site and a good selectivity relative to EBP-related s receptors. The most selective 2,6-dimethoxy deriv. (cis-33) demonstrated the highest potency (EC50 = 12.9 mM) and efficacy (70%) in inhibiting proliferation of human prostate cancer PC-3 cell line. Among the ref. compds., s2 agonist 36 (PB28) reached the max. efficacy (100%), suggesting the contribution of the s2 receptor to the antiproliferative activity. This novel class of EBP inhibitors represents a valuable tool for investigating the last steps of cholesterol biosynthesis and related pathologies, as well as a starting point for developing new anticancer drugs. |
|